

ASX ANNOUNCEMENT

2 April 2025

Update on Preparation of Preliminary Proxy Statement

Sunnyvale, California; 2 April 2025: EBR Systems, Inc. (ASX: “EBR”, “EBR Systems”, or the “Company”), developer of the world’s only wireless cardiac pacing device for heart failure, confirms that as advised in its announcement on 27 February 2025, EBR will hold its Annual Meeting of Stockholders (**Annual Meeting**) as a virtual meeting on Thursday, 22 May 2025 at 9:00am Australian Eastern Standard Time (Wednesday, 21 May 2025 at 4:00pm U.S. Pacific Daylight Time).

The Company has filed its preliminary proxy statement for the Annual Meeting (**Notice of Meeting**) with the United States Securities and Exchange Commission (**SEC**) for review. SEC rules require that the Notice of Meeting be publicly available during its review period, and it can be accessed [here](#). It has also been provided to the Australian Securities Exchange (**ASX**) for review. The preliminary Notice of Meeting is subject to change before its final release and dispatch to securityholders following the review period mandated by the SEC and the reviews conducted by the SEC and ASX.

The Notice of Meeting includes agenda items in relation to:

- the re-election of two Class I directors;
- the ratification and approval of a previous issuance of securities, pursuant to an institutional placement by the Company on 26 September 2024;
- the approval of an amendment to the 2021 Equity Incentive Plan (**Plan**) and the issue of securities under the Plan;
- a grant of options to the Company’s Chief Executive Officer;
- grants of options to the Company’s directors or their nominated holdings or entities;
- the approval of an amendment to the Certificate of Incorporation to reflect Delaware law provisions regarding exculpation of officers.

Communication to securityholders of the Company (both holders of common stock and CHES Depositary Interests) in relation to the Notice of Meeting will be dispatched on or around 11 April 2025. The Notice of Meeting will also be available on the ASX Market Announcements Platform and the Company’s website (www.ebrsystemsinc.com). The Notice of Meeting will provide details on how to view and listen to the meeting presentations, vote online and submit questions in real-time.

This announcement has been authorised for release by the Routine Disclosure Committee, a Committee of the Board.

For more information, please contact:

Company

Gary Doherty
Chief Financial Officer
P: +1 408 720 1906
E: info@ebrsystemsinc.com

Investors

Harry Halstead
Vesparum Capital
P: +61 3 8582 4800
E: EBRSystems@vesparum.com

About EBR Systems

Silicon Valley-based EBR Systems (ASX: EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

EBR Systems’ WiSE Technology

EBR SYSTEMS, INC. (ARBN 654 147 127)

480 Oakmead Parkway, Sunnyvale CA 94085 USA T: +1 408 720 1906 W: <https://ebrsystemsinc.com/>

EBR Systems' WiSE technology is the world's only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart's left ventricle. This has long been a goal of cardiac pacing companies since internal stimulation of the left ventricle is thought to be a potentially superior, more anatomically correct pacing location. WiSE technology enables cardiac pacing of the left ventricle with a novel cardiac implant that is roughly the size of a large grain of rice. The need for a pacing wire on the outside of the heart's left ventricle – and the attendant problems – are potentially eliminated. WiSE is an investigational device and is not currently available for sale in the US.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control, subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory applications and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. EBR does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. EBR may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Foreign Ownership Restriction

EBR's CHES Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of EBR's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act, or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.